Govaere, Olivier http://orcid.org/0000-0002-4426-6930
Hasoon, Megan http://orcid.org/0000-0002-0325-4298
Alexander, Leigh
Cockell, Simon http://orcid.org/0000-0002-6831-9806
Tiniakos, Dina
Ekstedt, Mattias
Schattenberg, Jörn M. http://orcid.org/0000-0002-4224-4703
Boursier, Jerome
Bugianesi, Elisabetta
Ratziu, Vlad http://orcid.org/0000-0002-6865-3791
Daly, Ann K.
Anstee, Quentin M. http://orcid.org/0000-0002-9518-0088
,
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (634413)
Innovative Medicines Initiative (777377)
Article History
Received: 15 December 2022
Accepted: 6 March 2023
First Online: 10 April 2023
Competing interests
: O.G. reports grants from NanoString Technologies. L.A. is employed by SomaLogic, Inc. D.T. reports consultation fees from Histoindex Pte Ltd. M.E. is a member of the advisory board at AMRA Medical AB. J.M.S. reports consultancy for Apollo Endosurgery, Albireo Pharma Inc, Bayer, BMS, Boehringer Ingelheim, Echosens, Genfit, Gilead Sciences, GSK, Heel GmbH, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, Julius Clinical, Madrigal, MSD, Nordic Bioscience, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Shinogi, Siemens Healthcare GmbH and Summit Clinical Research; research funding from Gilead Sciences, Boehringer Ingelheim, Nordic Bioscience and Siemens Healthcare GmbH; and speaker honoraria from MedPublico GmbH and Boehringer Ingelheim, all outside of the submitted work. J.B. consults for and received grants from Echosens and Siemens. E.B. served as a consultant or advisory board member for Boehringer Ingelheim, Gilead Sciences, Intercept, Inventiva, Merck, Novo Nordisk, Pfizer, ProSciento and a speaker for Gilead Sciences, MSD and Novo Nordisk, outside of the submitted work. Q.M.A. reports grants from European Commission during the conduct of the study; other grants from AstraZeneca, Boehringer Ingelheim, Intercept; consultancy for Alimentiv, Akero, AstraZeneca, Axcella, 89Bio, Boehringer Ingelheim, Bristol Myers Squibb, Galmed, Genfit, Genentech, Gilead, GlaxoSmithKline, Hanmi, HistoIndex, Intercept, Inventiva, Ionis, IQVIA, Janssen, Madrigal, Medpace, Merck, NGMBio, Novartis, Novo Nordisk, PathAI, Pfizer, Prosciento, Poxel, Resolution Therapeutics, Roche, Ridgeline Therapeutics, RTI, Shionogi, Terns. The remaining authors declare no competing interests.